Karuna Therapeutics Inc. (KRTX) Surges After Trial Meets Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Karuna Therapeutics Inc. (KRTX) PT Raised to $260 at Stifel
August 8, 2022 3:59 PM EDTStifel analyst Paul Matteis raised the price target on Karuna Therapeutics Inc. (NASDAQ: KRTX) to $260.00 (from $185.00) while maintaining a Buy rating.
The analyst comments "We rate KRTX shares Buy. Karuna is a biotechnology company focused on the development of novel neuroscience... More
Karuna Therapeutics Inc. (KRTX) PT Raised to $280 at Citi
August 8, 2022 1:01 PM EDTCiti analyst Neena Bitritto-Garg raised the price target on Karuna Therapeutics Inc. (NASDAQ: KRTX) to $280.00 (from $162.00) while maintaining a Buy rating.... More
Karuna Therapeutics Inc. (KRTX) PT Raised to $278 at Goldman Sachs
August 8, 2022 8:04 AM EDTGoldman Sachs analyst Salveen Richter raised the price target on Karuna Therapeutics Inc. (NASDAQ: KRTX) to $278.00 (from $228.00) while maintaining a Buy rating.... More
Zai Lab Limited (ZLAB) Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
August 8, 2022 7:12 AM EDTZai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the companys partner, Karuna Therapeutics, Inc. (NASDAQ: KRTX), reported positive topline results from its Phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT... More
"Great Scenario for KarXT" - Stifel Karuna Therapeutics (KRTX) at Buy
August 8, 2022 7:07 AM EDTStifel analyst Paul Matteis reiterated a Buy rating on Karuna Therapeutics Inc. (NASDAQ: KRTX) following the company's report of positive Phase 3 data from EMERGENT-2 trial.
The analyst comments: 'We reiterate our Buy rating on KRTX, on the back of positive ph3... More
